INVESTIGADORES
PESCE VIGLIETTI AyelÉn Ivana
artículos
Título:
Análisis del polimorfismo FcƴRIII en pacientes con cáncer de mama HER2+ en tratamiento neoadyuvante con Quimioterapia más trastuzumab y pertuzumab
Autor/es:
PESCE VIGLIETTI, AYELEN IVANA; BORDIGNON, MARÍA BELÉN; OSTINELLI, ALEXIS; CUETO, GERARDO; SANCHEZ, MARÍA BELÉN; PERAZZO, FLORENCIA; AMAT, MORA; COLÓ, FEDERICO; COSTANZO, MARÍA VICTORIA; NERVO, ADRIAN; NADAL, JORGE; CRIMI, GABRIEL; MC LEAN, IGNACIO; AMANCAY, EUNICE; MORDOH, JOSÉ; LEVY, ESTRELLA MARIEL
Revista:
Oncología Clínica
Editorial:
Asociación Argentina de Oncología Clínica
Referencias:
Lugar: Buenos Aires; Año: 2023 vol. 28
ISSN:
1669-6336
Resumen:
Trastuzumab (TRZ) was the first humanized IgG mAb approved for the treatment of breastcancer. Since its approval in 1998, it is estimated that it has been administered to more than 2.5million women worldwide and is on the WHO list of essential medicines. TRZ has revolutionizedHER2+ breast cancer therapy. Both non-immune and immune-mediated mechanisms explain theclinical activity of TRZ. The association between the FcγRIIIa polymorphism and the therapeutic efficacy of monoclonar antibodies (mAb) has been verified in several models. Patients with the F/V and V/F genotypes have a better clinical response when treated with different antibodies. However, there is controversial data on the association with the FcγRIIIa polymorphism and TRZ activity.
